| Q46003287 | A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. |
| Q41610409 | Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation |
| Q44435075 | Alveolar liquid clearance and sodium channel expression are decreased in transplanted canine lungs |
| Q37137488 | Alveolar macrophage secretory products effect type 2 pneumocytes undergoing hypoxia-reoxygenation. |
| Q24630502 | Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction |
| Q35855114 | Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction |
| Q37495663 | Atrial Fibrillation After Lung Transplantation: Incidence, Predictors and Long-Term Implications |
| Q44577940 | Beneficial effect of polyethylene glycol in lung preservation: early evaluation by proton nuclear magnetic resonance spectroscopy |
| Q74188539 | Beneficial effects of polyethylene glycol combined with low-potassium solution against lung ischemia/reperfusion injury in an isolated, perfused, functional pig lung |
| Q37755105 | Biomarkers of lung injury in primary graft dysfunction following lung transplantation |
| Q46017667 | Bronchiolitis obliterans is not the primary cause of death in pediatric living donor lobar lung transplant recipients. |
| Q33568643 | Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation |
| Q90019743 | Combined liver-lung transplantation: Indications, outcomes, current experience and ethical Issues |
| Q34238666 | Construct validity of the definition of primary graft dysfunction after lung transplantation. |
| Q35109013 | Critical care issues in lung and heart transplantation |
| Q38645350 | Development of a Multivariate Prediction Model for Early-Onset Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome in Lung Transplantation. |
| Q51528479 | Dynamic instability of central airways and peripheral airspace in rat lungs perfused with cold preservation solutions. |
| Q40852262 | Effects of EP4 solution and LPD solution vs Euro-Collins solution on Na(+)/K(+)-ATPase activity in rat alveolar type II cells and human alveolar epithelial cell line A549 cells |
| Q45898677 | Effects of exogenous surfactant on the non-heart-beating donor lung graft in experimental lung transplantation - a stereological study. |
| Q34532579 | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation |
| Q34815331 | Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction |
| Q34764561 | Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis |
| Q36758582 | Emerging drugs in lung transplantation |
| Q40957993 | Epidemiology and risk factors of multidrug-resistant bacteria in respiratory samples after lung transplantation |
| Q38023423 | Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success |
| Q90136209 | Fortification of Preservation Solution With Nitroprusside Does Not Alter Lung Allograft Survival in Clinical Human Lung Transplantation |
| Q73161663 | Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury |
| Q36807908 | Implications for Interleukin-33 in solid organ transplantation |
| Q35064032 | Inhaled nitric oxide and pulmonary vasoreactivity |
| Q73385565 | Ischemic preconditioning enhances donor lung preservation in the rabbit |
| Q44083744 | Low-flow venovenous CO₂ removal in association with lung protective ventilation strategy in patients who develop severe progressive respiratory acidosis after lung transplantation |
| Q56505206 | Lung Transplantation |
| Q47661825 | Lung graft dysfunction in the early postoperative period after lung and heart lung transplantation |
| Q35667648 | Lung transplant in end-staged chronic obstructive pulmonary disease (COPD) patients: a concise review |
| Q34149601 | Lung transplantation for chronic obstructive pulmonary disease |
| Q77366703 | Lung transplantation for cystic fibrosis |
| Q81732606 | Lung transplantation for emphysema |
| Q35293827 | Lung transplantation. Lung preservation. |
| Q36688194 | Microvesicles Derived From Human Mesenchymal Stem Cells Restore Alveolar Fluid Clearance in Human Lungs Rejected for Transplantation |
| Q44701806 | Modified reperfusion and ischemia-reperfusion injury in human lung transplantation |
| Q51697503 | Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). |
| Q50501971 | Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. |
| Q36486043 | Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation |
| Q39406812 | Outcomes of lung volume reduction surgery followed by lung transplantation: a matched cohort study |
| Q37280761 | Overview of lung transplantation |
| Q35625063 | Pediatric lung transplantation: update 2003. |
| Q34746010 | Perioperative care of the lung transplant patient |
| Q37393712 | Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs |
| Q90724236 | Pig lung transplant survival model |
| Q33653089 | Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation |
| Q37423137 | Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction |
| Q45131597 | Postoperative complications in the intensive care unit following lung transplantation in adults: results in University Hospital Reina Sofia |
| Q36030924 | Postoperative estradiol levels associate with development of primary graft dysfunction in lung transplantation patients |
| Q37218624 | Preoperative cardiac variables of diastolic dysfunction and clinical outcomes in lung transplant recipients |
| Q87441289 | Preoperative echocardiographic-defined moderate-severe pulmonary hypertension predicts prolonged duration of mechanical ventilation following lung transplantation for patients with COPD |
| Q37624976 | Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation. |
| Q36600647 | Pretreatment with bone marrow-derived mesenchymal stromal cell-conditioned media confers pulmonary ischemic tolerance |
| Q37670609 | Primary graft dysfunction. |
| Q28084783 | Primary graft dysfunction: lessons learned about the first 72 h after lung transplantation |
| Q36990120 | Priming donor lungs with thioredoxin-1 attenuates acute allograft injury in a rat model of lung transplantation |
| Q34576360 | Psychiatric issues in pulmonary disease |
| Q74319294 | Pulmonary "twinning" transplantation procedure |
| Q35740698 | Pulmonary complications of solid organ and hematopoietic stem cell transplantation |
| Q40598542 | Receptor for advanced glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation |
| Q95424132 | Risk factors and survival impact of primary graft dysfunction after lung transplantation in a single institution |
| Q46978312 | Risk factors for reperfusion injury after lung transplantation |
| Q47253255 | Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters |
| Q37414751 | Role of complement activation in obliterative bronchiolitis post-lung transplantation. |
| Q87595985 | Severe underweight decreases the survival rate in adult lung transplantation |
| Q34439910 | Shear stress-related mechanosignaling with lung ischemia: lessons from basic research can inform lung transplantation |
| Q57717858 | Short-term outcomes of lung transplant in idiopathic pulmonary fibrosis |
| Q38738172 | Significant role for microRNA-21 affecting toll-like receptor pathway in primary graft dysfunction after human lung transplantation |
| Q33650349 | Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation |
| Q54090679 | Superior protection in orthotopic rat lung transplantation with cyclic adenosine monophosphate and nitroglycerin-containing preservation solution. |
| Q73538967 | Temporary ECMO support following lung and heart-lung transplantation |
| Q36495273 | Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. |
| Q52540627 | The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. |
| Q36313833 | The biology of exhaled nitric oxide (NO) in ischemia-reperfusion-induced lung injury: a tale of dynamism of NO production and consumption |
| Q92619178 | The effect of primary graft dysfunction after lung transplantation on parenchymal remodeling detected by quantitative computed tomography |
| Q41762788 | The effect of primary graft dysfunction on survival after lung transplantation |
| Q92547617 | The ex vivo human lung: research value for translational science |
| Q35163115 | The perioperative management of patients with severe emphysema |
| Q36768114 | The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia |
| Q48419821 | Thioredoxin as a biomarker for graft rejection in lung transplant recipients |
| Q46843958 | Two-layer method (UW solution/perfluorochemical plus O2) for lung preservation in rat lung transplantation |
| Q36737002 | Update in transplantation 2006. |
| Q45830805 | Venovenous ECMO as a bridge to lung transplant and a protective strategy for subsequent primary graft dysfunction |
| Q44036233 | Why does the transplanted lung sometimes fail to work? |
| Q75344294 | [Lung preservation: current practices] |
| Q77541305 | [Single-lung transplant and primary graft failure] |